MNOV

MediciNova, Inc.

1.34 USD
-0.05 (-3.60%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MediciNova, Inc. stock is down 0% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 17 June’s closed higher than May.

About MediciNova, Inc.

MediciNova, Inc. focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders. MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the. treatment of acute exacerbations of asthma, MN-001 (tipelukast) is an orally bioavailable small molecule compound to treat fibrotic diseases.